Press Releases :: Sutro Biopharma, Inc. (STRO)

Dec 11, 2023 4:05 pm EST

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Dec 4, 2023 4:05 pm EST

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Nov 27, 2023 4:00 pm EST

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

Nov 21, 2023 4:05 pm EST

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Nov 13, 2023 4:30 pm EST

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Oct 22, 2023 4:25 am EDT

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Oct 16, 2023 4:05 pm EDT

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Sep 19, 2023 8:00 am EDT

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Aug 30, 2023 8:00 am EDT

Sutro Biopharma to Participate in Upcoming Investor Conferences

Aug 10, 2023 4:30 pm EDT

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones